Skip to main content

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

Recruiting · Not applicable · NCT05701917

Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome

At a glance

Research payments reported, 2025
$429,165
U.S. investigators named
33
Sites paid
9
Planned or actual enrollment
300

About the trial

Sponsor
Inari Medical
Tested
ClotTriever System (device), Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. (drug)
Dates
Started 2023-01-06; completion 2028-07-31
Results posted
Not yet

This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Stryker Corporation reported $429,165 in research payments for this study in 2025 (297 payments).

Products named: Flowtriever Catheter, S, Ct Thrombectomy System Kit

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.